Epidermal growth factor receptor (EGFR) mutation is currently the most common target; approximately 10% to 15% of the Caucasian population and more than 50% of Asian patients with non-squamous cell carcinoma carry this mutation (3–5). This evidence concerns the gene EGFR and squamous cell carcinoma.